Mylan

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Generic drugmaker Mylan NV  said on Tuesday reevaluation of its portfolio of medicines will continue next year and cautioned of a hit to revenue, and its shares nearly 6%.

Mylan shares slide after warning of hit to revenue

CFRA downgraded Mylan N.V. stock MYL, -6.40% to sell from hold on Tuesday, after the company's reported third-quarter earnings that showed adjusted EPS down 8% in the year to date and adjusted free cash flow down 36%.

Mylan shares slide 5.5% as CFRA downgrades to sell from hold

Mylan's (MYL) earnings beat estimates but sales miss the same in the third quarter of 2019. The company updates guidance for 2019.

Mylan's (MYL) Q3 Earnings Beat Estimates, Revenues Miss

Generic drug maker Mylan NV (NASDAQ: MYL) reported Tuesday ahead of the open with higher third-quarter revenue and GAAP earnings, although earnings declined year-over-year on an adjusted basis.

Mylan Q3 Non-GAAP EPS Beats Street Estimate; Drugmaker Narrows Guidance Range

Mylan stock jumped early Tuesday after the pharmaceutical company reported adjusted earnings of $1.17 per share, beating estimates. Sales of $2.96 billion came in below expectations.

Pharma Giant Mylan Jumps On Split Quarter As Earnings Beat Forecasts

Mylan NV shares MYL, +0.30% rose 2% in premarket trade Tuesday, after the company beat profit estimates for the third quarter and offered upbeat guidance.

Mylan tops profit estimates and offers upbeat guidance

Mylan (NASDAQ: MYL) announces its next round of earnings this Tuesday, November 5.

Mylan's Q3 Earnings Preview

Allergan

Catalent

Jazz Pharmaceuticals

Regeneron Pharmaceuticals

Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.

Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More

Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Mylan (MYL) Ahead of Earnings?

Investors will look forward to regular top and bottom-line numbers, when Mylan (MYL) reports Q3 results along with updates on merger with Upjohn.

Mylan (MYL) to Report Q3 Earnings: What's in the Offing?

Beyond Meat

Johnson & Johnson

Altria

iShares MSCI USA ESG Select ETF

Investors need to look beyond Balance Sheets and Income Statements.

These Companies Will Boost Your Portfolio Performance... And Your Morale

Mylan (MYL) sinks after the SEC charges it for misclassification of EpiPen.

Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen

Mylan will pay $30 million to settle a Securities and Exchange Commission lawsuit that claims the pharmaceutical company failed to disclose potential losses in the wake of an EpiPen scandal.
The post Pharma Giant Mylan To Pay $30 Million To Settle EpiPen Scandal appeared first on Investor's Business Daily.

Pharma Giant Mylan To Pay $30 Million To Settle EpiPen Scandal

Mylan NV  has agreed to pay a $30 million fine to settle U.S. Securities and Exchange Commission charges it hid from investors the impact of a federal probe into the drugmaker's overbilling the government for its EpiPen allergy treatment.

Mylan to pay $30 million U.S. SEC fine related to EpiPen overcharge probe

Mylan NV  will pay a $30 million civil fine to settle U.S. Securities and Exchange Commission charges it concealed a possible loss related to a federal probe on whether it overcharged Medicaid by hundreds of millions of dollars for sales of its EpiPen Auto-Injector.

Mylan to pay $30 million to settle U.S. SEC charges over EpiPen

The Securities and Exchange Commission settled charges Friday against Mylan N.V., MYL, +0.15% who agreed to pay $30 million for accounting and disclosure failures relating to a civil investigation over its alleged overcharging of Medicaid for EpiPen, its largest revenue and profit generating product.

SEC fines Mylan $30 million for Epipen disclosure failure

Home Depot

Newell Brands

The stock charts of NWL, HD and MYL are moving into curious positions as the trading week comes to a close.
The post 3 Big Stock Charts for Friday: Mylan, Newell and Home Depot appeared first on InvestorPlace.

3 Big Stock Charts for Friday: Mylan, Newell and Home Depot

Mylan stock popped Thursday after the Food and Drug Administration tentatively approved its generic version of Eli Lilly's chemotherapy, Alimta. Lilly stock also rose in afternoon action.

Mylan Stock Leaps As It Prepares To Knock Off $2 Billion Lilly Drug

Mylan (MYL) reported earnings 30 days ago. What's next for the stock?

Mylan (MYL) Down 12.9% Since Last Earnings Report: Can It Rebound?

Amgen

Bristol-Myers

Celgene

Biotech stocks overall are holding up fairly well amid recent market volatility. Look at which four biotech stocks to buy have staying power.

4 Biotech Stocks to Buy That Are on the Move

Novo Nordisk

News of Novo Nordisk suing Mylan is spreading as the two companies prepare for a legal battle over a generic version of Victoza.
The post Novo Nordisk Suing Mylan Over Generic Victoza Drug appeared first on InvestorPlace.

Novo Nordisk Suing Mylan Over Generic Victoza Drug

Novo Nordisk  said on Thursday it has filed litigation in a Delaware district court against Mylan  aimed at blocking its attempt to market a generic version of the Danish insulin maker's drug Victoza.

Denmark's Novo Nordisk files lawsuit against Mylan over patent

Is Mylan N.V. (MYL) a great pick from the value investor's perspective right now?

Should Value Investors Pick Mylan N.V. (MYL) Stock?

Over 60% of Mylan’s revenues are unaffected by the U.S. War on Drug Pricing.

Company Research: Mylan N.V.

Mylan NV  has reached a tentative agreement to pay $30 million to resolve a probe by the U.S. Securities and Exchange Commission related to its emergency allergy shot EpiPen, which became the center of a firestorm over price increases.

News for Mylan Stock (MYL)